Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden

Neurobiology of Aging

Volumn 45, Issue , 2016, Pages 212.e5-

  Ran, Caroline ^a   Brodin, Lovisa ^b   Forsgren, Lars ^c   Westerlund, Marie ^a   Ramezani, Mehrafarin ^a   Gellhaar, Sandra ^a   Xiang, Fengqing ^b   Fardell, Camilla ^d   Nissbrandt, Hans ^d   Söderkvist, Peter ^e   Puschmann, Andreas ^f   Ygland, Emil ^f   Olson, Lars ^a   Willows, Thomas ^b   Johansson, Anders ^b   Sydow, Olof ^b   Wirdefeldt, Karin ^a,b   Galter, Dagmar ^a   Svenningsson, Per ^b   Belin, Andrea Carmine ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e LINKÖPING UNIVERSITY   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Gaucher's disease; GBA; Genetics; Lysosome; Synuclein

Indexed keywords

GLUCOSYLCERAMIDASE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EFFECT SIZE; FEMALE; GAUCHER DISEASE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GLUCOCEREBROSIDASE GENE; HUMAN; HUMAN TISSUE; LYSOSOME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION RATE; ONSET AGE; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SWEDEN; VERY ELDERLY; GENETIC ASSOCIATION STUDY; GENETICS; MUTATION;

AGED; FEMALE; GENETIC ASSOCIATION STUDIES; GLUCOSYLCERAMIDASE; HUMANS; MALE; MUTATION; PARKINSON DISEASE; SWEDEN;

EID: 84975110901     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.04.022     Document Type: Article

References (53)

1. Aharon-Peretz, J., Rosenbaum, H., Gershoni-Baruch, R., Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351 (2004), 1972–1977.
2. Alcalay, R.N., Caccappolo, E., Mejia-Santana, H., Tang, M., Rosado, L., Orbe, R.M., Ruiz, D., Ross, B., Verbitsky, M., Kisselev, S., Louis, E., Comella, C., Colcher, A., Jennings, D., Nance, M., Bressman, S., Scott, W.K., Tanner, C., Mickel, S., Andrews, H., Waters, C., Fahn, S., Cote, L., Frucht, S., Ford, B., Rezak, M., Novak, K., Friedman, J.H., Pfeiffer, R., Marsh, L., Hiner, B., Siderowf, A., Payami, H., Molho, E., Factor, S., Ottman, R., Clark, L.N., Marder, K., Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 78 (2012), 1434–1440.
3. Alcalay, R.N., Levy, O.A., Waters, C.C., Fahn, S., Ford, B., Kuo, S.H., Mazzoni, P., Pauciulo, M.W., Nichols, W.C., Gan-Or, Z., Rouleau, G.A., Chung, W.K., Wolf, P., Oliva, P., Keutzer, J., Marder, K., Zhang, X., Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 138 (2015), 2648–2658.
4. Anheim, M., Elbaz, A., Lesage, S., Durr, A., Condroyer, C., Viallet, F., Pollak, P., Bonaiti, B., Bonaiti-Pellie, C., Brice, A., Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 78 (2012), 417–420.
5. Balicki, D., Beutler, E., Gaucher disease. Medicine (Baltimore) 74 (1995), 305–323.
6. Brady, R.O., Kanfer, J., Shapiro, D., The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J. Biol. Chem. 240 (1965), 39–43.
7. Carmine Belin, A., Westerlund, M., Sydow, O., Lundströmer, K., Håkansson, A., Nissbrandt, H., Olson, L., Galter, D., Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov. Disord. 21 (2006), 1731–1734.
8. Chabas, A., Gort, L., Diaz-Font, A., Montfort, M., Santamaria, R., Cidras, M., Grinberg, D., Vilageliu, L., Perinatal lethal phenotype with generalized ichthyosis in a type 2 Gaucher disease patient with the [L444P;E326K]/P182L genotype: effect of the E326K change in neonatal and classic forms of the disease. Blood Cells Mol Dis 35 (2005), 253–258.
9. Chiasserini, D., Paciotti, S., Eusebi, P., Persichetti, E., Tasegian, A., Kurzawa-Akanbi, M., Chinnery, P.F., Morris, C.M., Calabresi, P., Parnetti, L., Beccari, T., Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies. Mol. Neurodegener, 10, 2015, 15.
10. Clark, L.N., Kartsaklis, L.A., Wolf, G.R., Dorado, B., Ross, B.M., Kisselev, S., Verbitsky, M., Mejia-Santana, H., Cote, L.J., Andrews, H., Vonsattel, J.P., Fahn, S., Mayeux, R., Honig, L.S., Marder, K., Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch. Neurol. 66 (2009), 578–583.
11. Clark, L.N., Ross, B.M., Wang, Y., Mejia-Santana, H., Harris, J., Louis, E.D., Cote, L.J., Andrews, H., Fahn, S., Waters, C., Ford, B., Frucht, S., Ottman, R., Marder, K., Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69 (2007), 1270–1277.
12. Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu, K., Xu, K., Strathearn, K.E., Liu, F., Cao, S., Caldwell, K.A., Caldwell, G.A., Marsischky, G., Kolodner, R.D., Labaer, J., Rochet, J.C., Bonini, N.M., Lindquist, S., Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313 (2006), 324–328.
13. Cullen, V., Sardi, S.P., Ng, J., Xu, Y.H., Sun, Y., Tomlinson, J.J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., Rochet, J.C., Glicksman, M.A., Cheng, S.H., Grabowski, G.A., Shihabuddin, L.S., Schlossmacher, M.G., Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann. Neurol. 69 (2011), 940–953.
14. Dahl, N., Lagerstrom, M., Erikson, A., Pettersson, U., Gaucher disease type III (Norrbottnian type) is caused by a single mutation in exon 10 of the glucocerebrosidase gene. Am. J. Hum. Genet. 47 (1990), 275–278.
15. Dermentzaki, G., Dimitriou, E., Xilouri, M., Michelakakis, H., Stefanis, L., Loss of beta-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells. PLoS One, 8, 2013, e60674.
16. Do, C.B., Tung, J.Y., Dorfman, E., Kiefer, A.K., Drabant, E.M., Francke, U., Mountain, J.L., Goldman, S.M., Tanner, C.M., Langston, J.W., Wojcicki, A., Eriksson, N., Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet., 7, 2011, e1002141.
17. Du, T.T., Wang, L., Duan, C.L., Lu, L.L., Zhang, J.L., Gao, G., Qiu, X.B., Wang, X.M., Yang, H., GBA deficiency promotes SNCA/alpha-synuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy 11 (2015), 1803–1820.
18. Duran, R., Mencacci, N.E., Angeli, A.V., Shoai, M., Deas, E., Houlden, H., Mehta, A., Hughes, D., Cox, T.M., Deegan, P., Schapira, A.H., Lees, A.J., Limousin, P., Jarman, P.R., Bhatia, K.P., Wood, N.W., Hardy, J., Foltynie, T., The glucocerebrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov. Disord. 28 (2013), 232–236.
19. Gan-Or, Z., Amshalom, I., Kilarski, L.L., Bar-Shira, A., Gana-Weisz, M., Mirelman, A., Marder, K., Bressman, S., Giladi, N., Orr-Urtreger, A., Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 84 (2015), 880–887.
20. Gan-Or, Z., Giladi, N., Rozovski, U., Shifrin, C., Rosner, S., Gurevich, T., Bar-Shira, A., Orr-Urtreger, A., Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70 (2008), 2277–2283.
21. Gegg, M.E., Burke, D., Heales, S.J., Cooper, J.M., Hardy, J., Wood, N.W., Schapira, A.H., Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann. Neurol. 72 (2012), 455–463.
22. Gibb, W.R., Lees, A.J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51 (1988), 745–752.
23. Humphreys, K., Grankvist, A., Leu, M., Hall, P., Liu, J., Ripatti, S., Rehnstrom, K., Groop, L., Klareskog, L., Ding, B., Gronberg, H., Xu, J., Pedersen, N.L., Lichtenstein, P., Mattingsdal, M., Andreassen, O.A., O'Dushlaine, C., Purcell, S.M., Sklar, P., Sullivan, P.F., Hultman, C.M., Palmgren, J., Magnusson, P.K., The genetic structure of the Swedish population. PLoS One, 6, 2011, e22547.
24. Koressaar, T., Remm, M., Enhancements and modifications of primer design program Primer3. Bioinformatics 23 (2007), 1289–1291.
25. Kurzawa-Akanbi, M., Hanson, P.S., Blain, P.G., Lett, D.J., McKeith, I.G., Chinnery, P.F., Morris, C.M., Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. J. Neurochem. 123 (2012), 298–309.
26. Lesage, S., Anheim, M., Condroyer, C., Pollak, P., Durif, F., Dupuits, C., Viallet, F., Lohmann, E., Corvol, J.C., Honore, A., Rivaud, S., Vidailhet, M., Durr, A., Brice, A., Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum. Mol. Genet. 20 (2011), 202–210.
27. Lill, C.M., Roehr, J.T., McQueen, M.B., Kavvoura, F.K., Bagade, S., Schjeide, B.M., Schjeide, L.M., Meissner, E., Zauft, U., Allen, N.C., Liu, T., Schilling, M., Anderson, K.J., Beecham, G., Berg, D., Biernacka, J.M., Brice, A., DeStefano, A.L., Do, C.B., Eriksson, N., Factor, S.A., Farrer, M.J., Foroud, T., Gasser, T., Hamza, T., Hardy, J.A., Heutink, P., Hill-Burns, E.M., Klein, C., Latourelle, J.C., Maraganore, D.M., Martin, E.R., Martinez, M., Myers, R.H., Nalls, M.A., Pankratz, N., Payami, H., Satake, W., Scott, W.K., Sharma, M., Singleton, A.B., Stefansson, K., Toda, T., Tung, J.Y., Vance, J., Wood, N.W., Zabetian, C.P., Young, P., Tanzi, R.E., Khoury, M.J., Zipp, F., Lehrach, H., Ioannidis, J.P., Bertram, L., Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet., 8, 2012, e1002548.
28. Linder, J., Stenlund, H., Forsgren, L., Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study. Mov. Disord. 25 (2010), 341–348.
29. Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M.E., Sidransky, E., Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 81 (2004), 70–73.
30. Mao, X., Wang, T., Peng, R., Chang, X., Li, N., Gu, Y., Zhao, D., Liao, Q., Liu, M., Mutations in GBA and risk of Parkinson's disease: a meta-analysis based on 25 case-control studies. Neurol. Res. 35 (2013), 873–878.
31. Mata, I.F., Leverenz, J.B., Weintraub, D., Trojanowski, J.Q., Chen-Plotkin, A., Van Deerlin, V.M., Ritz, B., Rausch, R., Factor, S.A., Wood-Siverio, C., Quinn, J.F., Chung, K.A., Peterson-Hiller, A.L., Goldman, J.G., Stebbins, G.T., Bernard, B., Espay, A.J., Revilla, F.J., Devoto, J., Rosenthal, L.S., Dawson, T.M., Albert, M.S., Tsuang, D., Huston, H., Yearout, D., Hu, S.C., Cholerton, B.A., Montine, T.J., Edwards, K.L., Zabetian, C.P., GBA variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov. Disord. 31 (2016), 95–102.
32. Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A., Krainc, D., Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146 (2011), 37–52.
33. Montfort, M., Chabas, A., Vilageliu, L., Grinberg, D., Functional analysis of 13 GBA mutant alleles identified in Gaucher disease patients: pathogenic changes and “modifier” polymorphisms. Hum. Mutat. 23 (2004), 567–575.
34. Murphy, K.E., Gysbers, A.M., Abbott, S.K., Tayebi, N., Kim, W.S., Sidransky, E., Cooper, A., Garner, B., Halliday, G.M., Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 137 (2014), 834–848.
35. Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., DeStefano, A.L., Kara, E., Bras, J., Sharma, M., Schulte, C., Keller, M.F., Arepalli, S., Letson, C., Edsall, C., Stefansson, H., Liu, X., Pliner, H., Lee, J.H., Cheng, R., Ikram, M.A., Ioannidis, J.P., Hadjigeorgiou, G.M., Bis, J.C., Martinez, M., Perlmutter, J.S., Goate, A., Marder, K., Fiske, B., Sutherland, M., Xiromerisiou, G., Myers, R.H., Clark, L.N., Stefansson, K., Hardy, J.A., Heutink, P., Chen, H., Wood, N.W., Houlden, H., Payami, H., Brice, A., Scott, W.K., Gasser, T., Bertram, L., Eriksson, N., Foroud, T., Singleton, A.B., Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46 (2014), 989–993.
36. Nichols, W.C., Pankratz, N., Marek, D.K., Pauciulo, M.W., Elsaesser, V.E., Halter, C.A., Rudolph, A., Wojcieszek, J., Pfeiffer, R.F., Foroud, T., Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72 (2009), 310–316.
37. Pankratz, N., Beecham, G.W., DeStefano, A.L., Dawson, T.M., Doheny, K.F., Factor, S.A., Hamza, T.H., Hung, A.Y., Hyman, B.T., Ivinson, A.J., Krainc, D., Latourelle, J.C., Clark, L.N., Marder, K., Martin, E.R., Mayeux, R., Ross, O.A., Scherzer, C.R., Simon, D.K., Tanner, C., Vance, J.M., Wszolek, Z.K., Zabetian, C.P., Myers, R.H., Payami, H., Scott, W.K., Foroud, T., Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann. Neurol. 71 (2012), 370–384.
38. Pchelina, S.N., Nuzhnyi, E.P., Emelyanov, A.K., Boukina, T.M., Usenko, T.S., Nikolaev, M.A., Salogub, G.N., Yakimovskii, A.F., Zakharova, E.Y., Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases. Neurosci. Lett. 583 (2014), 188–193.
39. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., Sham, P.C., PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81 (2007), 559–575.
40. Puschmann, A., Heredity in Parkinson's disease. From rare mutations to common genetic risk factors. first ed., 2011, Media Tryck, Lund University, Lund, Sweden.
41. Ran, C., Belin, A.C., The genetics of Parkinson's disease: review of current and emerging candidates. J. Parkinsonism Restless Legs Syndr. 2014 (2014), 63–75.
42. Rocha, E.M., Smith, G.A., Park, E., Cao, H., Brown, E., Hayes, M.A., Beagan, J., McLean, J.R., Izen, S.C., Perez-Torres, E., Hallett, P.J., Isacson, O., Glucocerebrosidase gene therapy prevents alpha-synucleinopathy of midbrain dopamine neurons. Neurobiol. Dis. 82 (2015), 495–503.
43. Rodriguez, S., Gaunt, T.R., Day, I.N., Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169 (2009), 505–514.
44. Ronaghi, M., Uhlen, M., Nyren, P., A sequencing method based on real-time pyrophosphate. Science 281 (1998), 363–365.
45. Seto-Salvia, N., Pagonabarraga, J., Houlden, H., Pascual-Sedano, B., Dols-Icardo, O., Tucci, A., Paisan-Ruiz, C., Campolongo, A., Anton-Aguirre, S., Martin, I., Munoz, L., Bufill, E., Vilageliu, L., Grinberg, D., Cozar, M., Blesa, R., Lleo, A., Hardy, J., Kulisevsky, J., Clarimon, J., Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course. Mov. Disord. 27 (2012), 393–399.
46. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.M., Clark, L.N., Condroyer, C., De Marco, E.V., Durr, A., Eblan, M.J., Fahn, S., Farrer, M.J., Fung, H.C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A.E., Lee-Chen, G.J., Lesage, S., Marder, K., Mata, I.F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L.V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.K., Tayebi, N., Toda, T., Troiano, A.R., Tsuji, S., Wittstock, M., Wolfsberg, T.G., Wu, Y.R., Zabetian, C.P., Zhao, Y., Ziegler, S.G., Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361 (2009), 1651–1661.
47. Toft, M., Pielsticker, L., Ross, O.A., Aasly, J.O., Farrer, M.J., Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 66 (2006), 415–417.
48. Tsuang, D., Leverenz, J.B., Lopez, O.L., Hamilton, R.L., Bennett, D.A., Schneider, J.A., Buchman, A.S., Larson, E.B., Crane, P.K., Kaye, J.A., Kramer, P., Woltjer, R., Kukull, W., Nelson, P.T., Jicha, G.A., Neltner, J.H., Galasko, D., Masliah, E., Trojanowski, J.Q., Schellenberg, G.D., Yearout, D., Huston, H., Fritts-Penniman, A., Mata, I.F., Wan, J.Y., Edwards, K.L., Montine, T.J., Zabetian, C.P., GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 79 (2012), 1944–1950.
49. Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B.C., Remm, M., Rozen, S.G., Primer3—new capabilities and interfaces. Nucleic Acids Res., 40, 2012, e115.
50. Westerlund, M., Belin, A.C., Anvret, A., Håkansson, A., Nissbrandt, H., Lind, C., Sydow, O., Olson, L., Galter, D., Cerebellar alpha-synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. FASEB J. 22 (2008), 3509–3514.
51. Yap, T.L., Gruschus, J.M., Velayati, A., Westbroek, W., Goldin, E., Moaven, N., Sidransky, E., Lee, J.C., Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J. Biol. Chem. 286 (2011), 28080–28088.
52. Yap, T.L., Velayati, A., Sidransky, E., Lee, J.C., Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol. Genet. Metab. 108 (2013), 56–64.
53. Zuker, M., Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31 (2003), 3406–3415.